Psychiatrienet - User contributions [en]

Project:Background

2021-05-11T13:16:35Z

Walter:

__NOTOC__
More information and/or sources of switching antidepressants and antipsychotics

===Mission statement===
To improve independently psychopharmacotherapy and medication safety for all patients.

===Acknowledgements===
* ''' Walter Broekema,MSc, PharmD''': founder and past-editor-in-chief (2008-2018)
* ''' Ralph de Backer, MSc, PharmD''': benzodiazepines
* ''' Sietske Brouwer, MSc, PharmD''': maintenance
* ''' Jaap Kerkvliet, MSc, PharmD''': flagged revisions
* ''' Klaas Kooistra, MSc, PharmD''': moodstabilizers
* ''' Hélène Lichtenberg, MSc, PharmD''': hypericum switches
* ''' Ashni Lo-Kim-Lin, MSc, PharmD''': general
* ''' Lenneke Minjon, MSc, PharmD''': plain stopping antidepressants
* ''' Alexandra Mulder, MSc, PharmD''': antidepressants
* ''' Verena Mulder, MSc, PharmD''': antipsychotics
* ''' Mariska de Roo, PharmD''': general & authorization
* ''' Arent Storm, MSc''': website design & realization, technical and methodological supervision, benzo convertor
* ''' Arend Veeninga †, psychiatrist, PhD''': tester user interface
* ''' Mathilde van Veggel, MSc, PharmD''': maintenance
* ''' Anoek Verbeij, Bsc ''': maintenance
* ''' Joost van Raaij, MSc, PharmD''': maintenance

=== Work in progress ===
We are gradually improving the tables by adding more references, graphics etc. This will take time.

Project:Background

2018-10-23T15:50:13Z

Walter:

Project:Background

2018-10-23T15:50:01Z

Walter: /* Editor-in-chief */

Project:Background

2018-10-23T15:49:28Z

Walter:

Project:Background

2018-10-23T15:49:16Z

Walter:

Project:Background

2018-10-23T15:48:40Z

Walter: /* Editor-in-chief */

Project:Background

2018-10-23T14:53:45Z

Walter: /* Editor-in-chief */

File:Logo apotheek klein.jpg

2018-10-23T14:53:35Z

Walter:

Project:Background

2018-10-23T14:53:13Z

Walter:

Project:Background

2018-10-23T14:47:59Z

Walter: /* Editor-in-chief */

Project:Background

2018-10-23T14:45:55Z

Walter: /* Editor-in-chief */

File:Logo apotheek.jpg.png

2018-10-23T14:45:28Z

Walter: uploaded a new version of "File:Logo apotheek.jpg.png"

Project:Background

2018-10-23T14:44:23Z

Walter: /* Editor-in-chief */

File:Logo apotheek.jpg.png

2018-10-23T14:43:04Z

Walter:

Project:Background

2018-10-23T14:41:41Z

Walter: /* Editor-in-chief */

Project:Background

2018-10-23T14:37:49Z

Walter:

__NOTOC__
More information and/or sources of switching antidepressants and antipsychotics

===Mission statement===
To improve independently psychopharmacotherapy and medication safety for all patients.

===Editor-in-chief===
'''Walter Broekema (1953) is the founder and editor-in-chief of this WIKI'''.
[[image:WB paraplu.JPG|left|135px|Walter Broekema]]
He is now freelance hospital pharmacist. He was head of the clinical pharmacy department at [http://www.ggzcentraal.nl GGz Centraal] in Amersfoort, The Netherlands and had also pharmaceutical responsibility for a number of other Mental Health Institutions. He graduated as a pharmacist in 1979 and gained his specialisation `hospital pharmacist' in 1991. He has worked at university and community pharmacy. He is active in several organisations inside and outside the hospital, nationally and internationally. He is president of the Special Interest Group Psychiatry of the Dutch Association of Hospital Pharmacists (NVZA/KNMP). He initiated the ATC-drug-distribution robot, started an early audiovisual quality manual and is active in several E-projects like this one. One of his favourites is multidisciplinary cooperation and education. He actively participates in (inter)national conferences. <br />Conflict of interests: no pharmaceutical companies nor financial interest is involved. Declared 2015.
<br clear="all">

===Acknowledgements===
* ''' Ralph de Backer, MSc, PharmD''': benzodiazepines
* '''Walter Broekema is the founder and past-editor-in-chief'''
* ''' Sietske Brouwer, MSc, PharmD''': maintenance
* ''' Jaap Kerkvliet, MSc, PharmD''': flagged revisions
* ''' Klaas Kooistra, MSc, PharmD''': moodstabilizers
* ''' Hélène Lichtenberg, MSc, PharmD''': hypericum switches
* ''' Ashni Lo-Kim-Lin, MSc, PharmD''': general
* ''' Lenneke Minjon, MSc, PharmD''': plain stopping antidepressants
* ''' Alexandra Mulder, MSc, PharmD''': antidepressants
* ''' Verena Mulder, MSc, PharmD''': antipsychotics
* ''' Mariska de Roo, PharmD''': general & authorization
* ''' Arent Storm, MSc''': website design & realization, technical and methodological supervision, benzo convertor
* ''' Arend Veeninga †, psychiatrist, PhD''': tester user interface
* ''' Mathilde van Veggel, MSc, PharmD''': maintenance
* ''' Anoek Verbeij, Bsc ''': maintenance

=== Work in progress ===
We are gradually improving the tables by adding more references, graphics etc. This will take time.

Fluoxetine-tranylcypromine

2016-10-06T15:02:29Z

Walter: Reverted edits by Zoe (talk) to last revision by Anoek

{{Drugswitch
| from = fluoxetine
| to = tranylcypromine
| stop =
{{stopFluoxetine1}}

| start =
* '''Day 1-35:''' a wash-out period of five weeks is necessary because of the long half live.
* '''Day 36:''' start tranylcypromine in a low dosage of 20 mg/day for one week.
* '''Day 43:''' after this week gradually increase the dosage of tranylcypromine.
| caveat =
{{caveSS}}
|info=
* Desmethylfluoxetine has a half live of about one week so a long wash-out period is necessary.
}}

Imipramine-tranylcypromine

2016-10-04T12:45:28Z

Walter:

{{Drugswitch
| from = imipramine
| to = tranylcypromine
| stop =
{{generaldecrease25p3d}}
* Because of the half life of desipramine of up to 3 days a washout period of 2 weeks is necessary<ref>DrugBank[http://www.drugbank.ca/drugs/DB01151]</ref>
| start =
{{Starttranyl}}
| caveat =
{{caveSS}}
}}

Imipramine-tranylcypromine

2016-10-04T12:41:59Z

Walter:

{{Drugswitch
| from = imipramine
| to = tranylcypromine
| stop =
{{generaldecrease25p3d}}
* Because of the half life of desipramine of up to 3 days a washout period of 2 weeks is necessary<ref [DrugBank http://www.drugbank.ca/drugs/DB01151]</references>
| start =
{{Starttranyl}}
| caveat =
{{caveSS}}
}}

Imipramine-tranylcypromine

2016-10-04T12:40:58Z

Walter:

{{Drugswitch
| from = imipramine
| to = tranylcypromine
| stop =
{{generaldecrease25p3d}}
* Because of the half life of desipramine of up to 3 days a washout period of 2 weeks is necessary<ref DrugBank[http://www.drugbank.ca/drugs/DB01151]</references>
| start =
{{Starttranyl}}
| caveat =
{{caveSS}}
}}

Imipramine-tranylcypromine

2016-10-04T12:40:19Z

Walter:

{{Drugswitch
| from = imipramine
| to = tranylcypromine
| stop =
{{generaldecrease25p3d}}
* Because of the half life of desipramine of up to 3 days a washout period of 2 weeks is necessary<ref DrugBank[http://www.drugbank.ca/drugs/DB01151]</ref>
| start =
{{Starttranyl}}
| caveat =
{{caveSS}}
}}

Mirtazapine-tranylcypromine

2016-10-04T12:38:29Z

Walter:

{{Drugswitch
| from = mirtazapine
| to = tranylcypromine
| stop =
{{generaldecrease25p3d}}
{{nowashout}}
| start =
{{Starttranyl}}
| info =
{{nointeractions}}<ref>Kennisbank KNMP[https://kennisbank.knmp.nl/article/interacties/3611.html]</ref>
}}

Mirtazapine-tranylcypromine

2016-10-04T12:37:44Z

Walter:

{{Drugswitch
| from = mirtazapine
| to = tranylcypromine
| stop =
{{generaldecrease25p3d}}
{{nowashout}}
| start =
{{Starttranyl}}
| info =
{{nointeractions}} <ref>Kennisbank KNMP[https://kennisbank.knmp.nl/article/interacties/3611.html]</ref>
}}

Imipramine-tranylcypromine

2016-10-04T12:36:16Z

Walter:

{{Drugswitch
| from = imipramine
| to = tranylcypromine
| stop =
{{generaldecrease25p3d}}
* Because of the half life of desipramine of up to 3 days a washout period of 2 weeks is necessary <ref DrugBank [http://www.drugbank.ca/drugs/DB01151]</ref>
| start =
{{Starttranyl}}
| caveat =
{{caveSS}}
}}

Template:3Wwashout

2016-10-04T12:22:44Z

Walter:

*Stop and wait for a 3 week washout period

Mirtazapine-tranylcypromine

2016-10-04T12:16:50Z

Walter:

{{Drugswitch
| from = mirtazapine
| to = tranylcypromine
| stop =
{{generaldecrease25p3d}}
{{nowashout}}
| start =
{{Starttranyl}}
| info =
{{nointeractions}} <ref>Kennisbank KNMP"[https://kennisbank.knmp.nl/article/interacties/3611.html]</ref>
}}

Mirtazapine-tranylcypromine

2016-10-04T12:15:58Z

Walter:

{{Drugswitch
| from = mirtazapine
| to = tranylcypromine
| stop =
{{generaldecrease25p3d}}
{{nowashout}}
| start =
{{Starttranyl}}
| info =
{{nointeractions}} <ref> name="Kennisbank KNMP"[https://kennisbank.knmp.nl/article/interacties/3611.html]Kennisbank KNMP</ref>
}}

Mirtazapine-tranylcypromine

2016-10-04T12:14:29Z

Walter:

{{Drugswitch
| from = mirtazapine
| to = tranylcypromine
| stop =
{{generaldecrease25p3d}}
{{nowashout}}
| start =
{{Starttranyl}}
| info =
{{nointeractions}} <ref>[https://kennisbank.knmp.nl/article/interacties/3611.html]Kennisbank KNMP</ref>
}}

Mirtazapine-tranylcypromine

2016-10-04T12:12:37Z

Walter:

{{Drugswitch
| from = mirtazapine
| to = tranylcypromine
| stop =
{{generaldecrease25p3d}}
{{nowashout}}
| start =
{{Starttranyl}}
| info =
{{nointeractions}} <ref name="Kennisbank KNMP">[https://kennisbank.knmp.nl/article/interacties/3611.html]</ref>
}}

Template:Starttranyl

2016-10-04T12:00:08Z

Walter:

*Start tranylcypromine in a low dosage of 20 mg/day for one week.
*After this week the dosage of tranylcypromine can be increased.

Sertraline-tranylcypromine

2016-09-22T13:03:57Z

Walter: Reverted edits by Zoe (talk) to last revision by Anoek

{{Drugswitch
| from = sertraline
| to = tranylcypromine
| stop =
{{stopSertraline}}

| start =
* '''Day 9-23:''' a wash-out period of 2 weeks is necessary.
* '''Day 24:''' start tranylcypromine the next day in a low dosage of 20 mg/day for one week.
* '''Day 31:''' after this week the dosage of tranylcypromine can be increased gradually.
|caveat =
{{caveSS}}
{{SSRI14d}}
}}

Trazodone-tranylcypromine

2016-09-22T13:02:41Z

Walter: Reverted edits by Zoe (talk) to last revision by Anoek

{{ Drugswitch
| from = trazodone
| to = tranylcypromine
| stop =
{{stopTrazodone}}
| start =
* '''Day 8-10:''' a wash-out period of 3 days is necessary.
* '''Day 11:''' start administration of tranylcypromine in a dosage of 20 mg/day.
* If necessary, increase dosage of tranylcypromine.
| info =
* {{theorSS}}
{{trazoTablet}}
}}

Venlafaxine-tranylcypromine

2016-09-22T13:01:31Z

Walter: Reverted edits by Zoe (talk) to last revision by Anoek

{{Drugswitch
| from = venlafaxine
| to = tranylcypromine
| stop =
{{stopVenlafaxine}}
| start =
{{washout8-14}}
* '''Day 15:''' start administration of tranylcypromine in a low dosage of 20 mg/day for one week.
* '''Day 22:''' after this week the dosage of tranylcypromine can be increased if necessary.
| caveat =
{{caveSS}}

}}

Vortioxetine-agomelatine

2016-09-22T09:22:42Z

Walter:

{{Drugswitch
| from = Vortioxetine
| to = agomelatine
| stop =
| stop =
{{stopVortioxetine}}
| start =
* '''Day 9:''' start administration of agomelatine in a dosage of 25 mg/day.
* '''Day 23:''' if necessary, increase dosage of agomelatine to 50 mg/day.<ref name="agoswitch"> {{Pubmed|20196187|McAllister-Williams RH et al. The use of antidepressants in clinical practice: focus on agomelatine. Hum Psychopharmacol. 2010 Mar 1;25(2):95-102}}</ref>

|info = * References <ref name="vortiswitch"> {{Pubmed|24570588 |Katona et al. New generation multi-modal antidepressants: focus on vortioxetine for major depressive disorder. 2014 2014 Feb 19;10:349-54}}</ref> <ref name="informatorium">{{KNMP|vortioxetine}}</ref> <ref name="Summary of Product Characteristics"> [http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002717/WC500159449.pdf Summary of Product Characteristics Vortioxetine]</ref>

}}

Vortioxetine-agomelatine

2016-09-22T09:21:19Z

Walter:

Vortioxetine-agomelatine

2016-09-22T09:15:52Z

Walter:

{{Drugswitch
| from = Vortioxetine
| to = agomelatine
| stop =
| stop =
{{stopVortioxetine}}
| start =
* '''Day 9:''' start administration of agomelatine in a dosage of 25 mg/day.
* '''Day 23:''' if necessary, increase dosage of agomelatine to 50 mg/day.<ref name="agoswitch"> {{Pubmed|20196187|McAllister-Williams RH et al. The use of antidepressants in clinical practice: focus on agomelatine. Hum Psychopharmacol. 2010 Mar 1;25(2):95-102}}</ref>

|info = * References <ref name="vortiswitch"> {{Pubmed|24570588 |Katona et al. New generation multi-modal antidepressants: focus on vortioxetine for major depressive disorder. 2014 2014 Feb 19;10:349-54}}</ref> <ref name="informatorium">{{KNMP|vortioxetine}}</ref> <ref name="Summary of Product Characteristics">http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002717/WC500159449.pdf</ref>

}}

Vortioxetine-agomelatine

2016-09-22T09:15:04Z

Walter:

{{Drugswitch
| from = Vortioxetine
| to = agomelatine
| stop =
| stop =
{{stopVortioxetine}}
| start =
* '''Day 9:''' start administration of agomelatine in a dosage of 25 mg/day.
* '''Day 23:''' if necessary, increase dosage of agomelatine to 50 mg/day.<ref name="agoswitch"> {{Pubmed|20196187|McAllister-Williams RH et al. The use of antidepressants in clinical practice: focus on agomelatine. Hum Psychopharmacol. 2010 Mar 1;25(2):95-102}}</ref>

|info = * References <ref name="vortiswitch"> {{Pubmed|24570588 |Katona et al. New generation multi-modal antidepressants: focus on vortioxetine for major depressive disorder. 2014 2014 Feb 19;10:349-54}}</ref>
<ref name="informatorium">{{KNMP|vortioxetine}}</ref>
<ref name="Summary of Product Characteristics">http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002717/WC500159449.pdf</ref>

}}

Vortioxetine-agomelatine

2016-09-22T09:11:47Z

Walter:

Vortioxetine-agomelatine

2016-09-22T09:11:11Z

Walter:

{{Drugswitch
| from = Vortioxetine
| to = agomelatine
| stop =
| stop =
{{stopVortioxetine}}
| start =
* '''Day 9:''' start administration of agomelatine in a dosage of 25 mg/day.
* '''Day 23:''' if necessary, increase dosage of agomelatine to 50 mg/day.<ref name="agoswitch"> {{Pubmed|20196187|McAllister-Williams RH et al. The use of antidepressants in clinical practice: focus on agomelatine. Hum Psychopharmacol. 2010 Mar 1;25(2):95-102}}</ref>

|info = * see references <ref name="vortiswitch"> {{Pubmed|24570588 |Katona et al. New generation multi-modal antidepressants: focus on vortioxetine for major depressive disorder. 2014 2014 Feb 19;10:349-54}}</ref> <ref name="informatorium">{{KNMP|vortioxetine}}</ref>
}}

Vortioxetine-agomelatine

2016-09-22T09:10:36Z

Walter:

{{Drugswitch
| from = Vortioxetine
| to = agomelatine
| stop =
| stop =
{{stopVortioxetine}}
| start =
* '''Day 9:''' start administration of agomelatine in a dosage of 25 mg/day.
* '''Day 23:''' if necessary, increase dosage of agomelatine to 50 mg/day.<ref name="agoswitch"> {{Pubmed|20196187|McAllister-Williams RH et al. The use of antidepressants in clinical practice: focus on agomelatine. Hum Psychopharmacol. 2010 Mar 1;25(2):95-102}}</ref>
|info = see references <ref name="vortiswitch"> {{Pubmed|24570588 |Katona et al. New generation multi-modal antidepressants: focus on vortioxetine for major depressive disorder. 2014 2014 Feb 19;10:349-54}}</ref> <ref name="informatorium">{{KNMP|vortioxetine}}</ref>
}}

Vortioxetine-agomelatine

2016-09-22T09:08:19Z

Walter:

{{Drugswitch
| from = Vortioxetine
| to = agomelatine
| stop =
| stop =
{{stopVortioxetine}}
| start =
* '''Day 9:''' start administration of agomelatine in a dosage of 25 mg/day.
* '''Day 23:''' if necessary, increase dosage of agomelatine to 50 mg/day.<ref name="agoswitch"> {{Pubmed|20196187|McAllister-Williams RH et al. The use of antidepressants in clinical practice: focus on agomelatine. Hum Psychopharmacol. 2010 Mar 1;25(2):95-102}}</ref>
* Information: see references <ref name="vortiswitch"> {{Pubmed|24570588 |Katona et al. New generation multi-modal antidepressants: focus on vortioxetine for major depressive disorder. 2014 2014 Feb 19;10:349-54}}</ref> <ref name="informatorium">{{KNMP|vortioxetine}}</ref>
}}

Vortioxetine-agomelatine

2016-09-22T09:07:39Z

Walter:

{{Drugswitch
| from = Vortioxetine
| to = agomelatine
| stop =
| stop =
{{stopVortioxetine}}
| start =
* '''Day 9:''' start administration of agomelatine in a dosage of 25 mg/day.
* '''Day 23:''' if necessary, increase dosage of agomelatine to 50 mg/day.<ref name="agoswitch"> {{Pubmed|20196187|McAllister-Williams RH et al. The use of antidepressants in clinical practice: focus on agomelatine. Hum Psychopharmacol. 2010 Mar 1;25(2):95-102}}</ref>
* More information: see references <ref name="vortiswitch"> {{Pubmed|24570588 |Katona et al. New generation multi-modal antidepressants: focus on vortioxetine for major depressive disorder. 2014 2014 Feb 19;10:349-54}}</ref> <ref name="informatorium">{{KNMP|vortioxetine}}</ref>
}}

Vortioxetine-agomelatine

2016-09-22T09:07:08Z

Walter:

{{Drugswitch
| from = Vortioxetine
| to = agomelatine
| stop =
| stop =
{{stopVortioxetine}}
| start =
* '''Day 9:''' start administration of agomelatine in a dosage of 25 mg/day.
* '''Day 23:''' if necessary, increase dosage of agomelatine to 50 mg/day.<ref name="agoswitch"> {{Pubmed|20196187|McAllister-Williams RH et al. The use of antidepressants in clinical practice: focus on agomelatine. Hum Psychopharmacol. 2010 Mar 1;25(2):95-102}}</ref>
* More information: see references
<ref name="vortiswitch"> {{Pubmed|24570588 |Katona et al. New generation multi-modal antidepressants: focus on vortioxetine for major depressive disorder. 2014 2014 Feb 19;10:349-54}}</ref> <ref name="informatorium">{{KNMP|vortioxetine}}</ref>
}}

Nortriptyline-amitriptyline

2016-09-22T08:56:28Z

Walter:

{{Drugswitch
| from = nortriptyline
| to = amitriptyline
| stop =
{{TCAdecrease25p3d}}
| start =
*Simultaneously, at the same time of the decrease
{{TCAincrease25p3d}}
| info =
* {{TCAantichol}}
}}

Nortriptyline-amitriptyline

2016-09-22T08:53:03Z

Walter:

{{Drugswitch
| from = nortriptyline
| to = amitriptyline
| stop =
{{TCAdecrease25p3d}}
| start =
*Simultaneously
{{TCAincrease25p3d}}
| info =
* {{TCAantichol}}
}}

Nortriptyline-amitriptyline

2016-08-31T14:35:17Z

Walter:

{{Drugswitch
| from = nortriptyline
| to = amitriptyline
| stop =
{{TCAdecrease25p3d}}
| start =
Simultaneously
{{TCAincrease25p3d}}
| info =
* {{TCAantichol}}
}}

Template:TCAplasmalevelmonitoring

2016-08-31T12:29:05Z

Walter:

* Plasma monitoring for TCA's is advisable, because of plasma-reponse relations, genetic polymorphism and under or overdosing.<ref name="Plasma monitoring of TCA's">[[http://tdm-monografie.org/monografie/tca-tricyclische-antidepressiva]]</ref>

Template:TCAplasmalevelmonitoring

2016-08-31T12:27:54Z

Walter:

* Plasma monitoring for TCA's is advisable, because of plasma-reponse relations, genetic polymorphism and under or overdosing.<ref>test</ref>

Template:TCAplasmalevelmonitoring

2016-08-31T12:26:46Z

Walter:

* Plasma monitoring for TCA's is advisable, because of plasma-reponse relations, genetic polymorphism and under or overdosing.<ref name="TDM monografie TCA's>"</ref>

Template:TCAplasmalevelmonitoring

2016-08-31T12:24:43Z

Walter:

* Plasma monitoring for TCA's is advisable, because of plasma-reponse relations, genetic polymorphism and under or overdosing.<ref name="TDM monografie TCA's>"[[http://tdm-monografie.org/monografie/tca-tricyclische-antidepressiva]]</ref>